Real-World study tracks Zanubrutinib's impact on blood cancer patients

NCT ID NCT05326308

Recruiting now Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab). Researchers will track hospital visits, quality of life, and how well the drug works in routine medical practice. The goal is to fill gaps in real-world data for these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (Brukinsa) and obinutuzumab (Gazyvaro)
What this could lead to: If successful, this study could show how well zanubrutinib works in real-world settings and help improve treatment guidelines for these blood cancers.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or incomplete data. It won't prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia follicular lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA FOLLICULAR LYMPHOMA MARGINAL ZONE LYMPHOMA WALDENSTRÖM'S MACROGLOBULINEMIA

Contacts and locations

Locations

Lübecker Onkologische Schwerpunktpraxis
RECRUITING

Lübeck, Schleswig-Holstein, D-23562, Germany
Universitätsklinikum Salzburg, Klinik für Innere Medizin III
RECRUITING

Salzburg, A-5020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.